Open Access

Profiling of the perturbed metabolomic state of mouse spleen during acute and chronic toxoplasmosis

Parasites & Vectors201710:339

https://doi.org/10.1186/s13071-017-2282-6

Received: 1 April 2017

Accepted: 10 July 2017

Published: 18 July 2017

Abstract

Background

Toxoplasma gondii, a common opportunistic protozoan, is a leading cause of illness and mortality among immunosuppressed individuals and during congenital infections. Current therapeutic strategies for toxoplasmosis are not fully effective at curtailing disease progression in these cases. Given the parasite ability to influence host immunity and metabolism, understanding of the metabolic alterations in the host’s immune organs during T. gondii infection may enhance the understanding of the molecular mechanisms that define the pathophysiology of T. gondii infection.

Methods

We investigated the global metabolic changes in the spleen of BALB/c mice at early and late stage of infection with T. gondii using LC-MS/MS-based metabolomics. Multivariate data analysis methods, principal components analysis (PCA) and partial least squares discriminant analysis (PLS-DA), were used to identify metabolites that are influenced by T. gondii infection.

Results

Multivariate analyses clearly separated the metabolites of spleen of infected and control mice. A total of 132 differential metabolites were identified, 23 metabolites from acutely infected versus control mice and 109 metabolites from chronically infected versus control mice. Lipids, hormones, lactones, acids, peptides, antibiotics, alkaloids and natural toxins were the most influenced chemical groups. There were 12 shared differential metabolites between acutely infected versus control mice and chronically infected versus control mice, of which 4,4-Dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol was significantly upregulated and ubiquinone-8 was significantly downregulated. Major perturbed metabolic pathways included primary bile acid biosynthesis, steroid hormone biosynthesis, biotin metabolism, and steroid biosynthesis, with arachidonic acid metabolism being the most significantly impacted pathway. These metabolic changes suggest a multifactorial nature of the immunometabolic responses of mouse spleen to T. gondii infection.

Conclusions

This study demonstrated that T. gondii infection can cause significant metabolomic alterations in the spleen of infected mice. These findings provide new insights into the molecular mechanisms that underpin the pathogenesis of T. gondii infection.

Keywords

Toxoplasma gondii SpleenMass spectrometryMetabolomeNon-targeted metabolomicsPathway enrichment analysis

Background

Toxoplasmosis is a common opportunistic infection caused by Toxoplasma gondii, which can infect almost all warm-blooded vertebrate animals [1]. This parasite is also highly zoonotic, with roughly one-third of the world population reported to be infected [2]. Toxoplasma gondii infections of healthy, immunocompetent individuals are usually asymptomatic [3, 4]. However, T. gondii can cause significant morbidity and mortality under certain conditions, such as AIDS, bone marrow or solid organ transplantations, or if infection occurs during pregnancy [3, 4]. Toxoplasma gondii infection can manifest as an acute infection attributed to the replicating tachyzoite stage, which results in significant immune activation and systemic dissemination to various host tissues [5]. In the presence of an effective immune response, tachyzoites transform into slowly replicating bradyzoites, which exist in the brain and muscle tissue in the form of cysts and this marks the chronic phase of the infection [6, 7]. Control of T. gondii replication and transition to the latent form depends on cell-mediated immunity; however, humoral immunity is also critical for resistance to T. gondii infection [8, 9].

In recent years, the integration between what used to be traditionally distinct fields, immunology and metabolism, has spurred the emergence of a new discipline called immune system metabolism or “immunometabolism”. Previous studies have shown that metabolic changes in the body are connected to immune regulation. For example, amino acids can modulate the immune function by regulating lymphocyte proliferation and cytokine production [10]. Also, abnormal metabolism of phospholipids, urea, and amino acids can trigger the immune responses and inflammatory processes in Alzheimer’s disease [11]. Interestingly, the interaction between immunity and metabolism has also been shown to play a key role in the pathogenesis of T. gondii. Infection with this parasite can evoke major metabolic reprogramming of host cells [12, 13]. In the interim, immunoinflammation is a common feature associated with T. gondii infection, in the brain and peripheral circulation [14]. Also, T. gondii employs various immunoregulatory mechanisms of evading or subverting host defenses in order to persist as a dormant stage and to ensure transmission to the subsequent host [15]. These mechanisms include, for example, alteration in the architecture of spleen, dysregulation of the expression of cytokines, and generation of anti-parasitic humoral immune response [16].

Surprisingly, investigation of peripheral immune organs that could be affected by systemic perturbations occurring during toxoplasmosis has not been addressed yet. Spleen is a major immune organ playing a critical role in the innate and adaptive immune responses. It is mainly made up of red and white pulp. The white pulp includes B cell and T cell zones, and activates specific immune responses that protect individuals against microbial infection. Knowledge of the metabolic composition of spleen during T. gondii infection may reveal the underlying molecular and immune-regulatory processes that operate to counter T. gondii infection. Metabolomics has been a powerful tool for the simultaneous quantitative measurement of many metabolites in response of individuals or organisms to drug treatment or other interventions [17] or to study host-parasite interaction [18]. Liquid chromatography coupled to mass spectrometry (LC-MS), including targeted LC-MS and non-targeted LC-MS, has been widely applied to identify and quantify metabolites [12, 13]. We previously employed non-targeted metabolomics to assess the metabolic changes in the brain and serum of mice at different stages of T. gondii infection [12, 13]. These studies revealed a profound impact of T. gondii on host metabolism, with numerous pathways being affected, and some of the most impacted pathways were related to the metabolism of amino acids, energy metabolism and immune signaling [13].

Given the intricate relationship between immunity and metabolism, and given the importance of spleen in generating anti-T. gondii immune response, metabolic fingerprinting of spleen tissues might provide important information about the metabolic alterations that underpin the immunologic responses during T. gondii infection. In this work, we hypothesized that spleen exhibits distinct metabolomic patterns in response to T. gondii infection, which could result in different spleen functions, particularly affecting the immune response to infection. To test this hypothesis, we investigated, for the first time, changes in the metabolism of spleen of mice infected with T. gondii during acute and chronic phases of infection using non-targeted LC-MS/MS metabolomics. Our findings confirmed that using LC-MS/MS-based metabolomics coupled to chemometric methods can provide a powerful approach for discerning metabolic changes in the spleen of mice infected with T. gondii and for elucidating infection stage-specific metabolic profiles.

Methods

Animal infection

Six-week-old, female, BALB/c mice were obtained from the Laboratory Animal Center of Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences. Mice were housed in microisolator cages under specific-pathogen free (SPF) conditions, with controlled temperature (22 ± 2 °C), 12 h light/ dark cycles and were given water and standard food pellets ad libitum. Mice (n = 39) were randomly allocated into two groups: infected group (n = 26) and control group (n = 13). Toxoplasma gondii type II Prugniuad (Pru) strain was maintained in mice via oral inoculation of the parasite cysts that were isolated from mice brain tissues 40 days post-infection (dpi). Each mouse in the infected group was infected orally with 10 cysts of T. gondii Pru strain in 100 μl phosphate buffered saline solution (PBS). Control mice were gavaged with an equivalent volume of PBS only. All mice were observed daily throughout the entire experiment.

Tissue collection and detection of infection

To correlate changes in spleen metabolism by stage of infection, we collected spleen samples at 11 and 30 dpi, which were correlated with the acute and chronic stages of infection, respectively. In our previous studies, mice infected with T. gondii exhibited acute clinical signs at 7 dpi, which declined gradually until disappearing after 21 dpi [12, 13]. Also, transcriptional changes observed in T. gondii-infected mice at 10 and 28 dpi were correlated with acute and chronic infection, respectively [19]. Spleens from uninfected (control) mice were also collected at 30 dpi. Mice were anesthetized by isoflurane inhalation and sacrificed by exsanguination via cardiac puncture. Spleen was rapidly removed, rinsed with saline solution (0.9% NaCl w/v), snap-frozen in liquid nitrogen, and stored at -80 °C until analysis. Tissues from other organs, including brain, blood, liver, lung, small intestine and kidney, were examined for the presence of T. gondii, as previously described [20]. Briefly, genomic DNA was extracted from these various tissues using QIAamp® DNA Mini kit following the manufacturer’s instructions (QIAGEN, Hilden, Germany). DNA was then used as a template for PCR to amplify T. gondii B1 gene using the specific primers (5′-AAC GGG CGA GTA GCA CCT GAG GAG-3′ and 5′-TGG GTC TAC GTC GAT GGC ATG ACA AC-3′). Positive control (DNA from T. gondii) and negative control (deionized water) samples were included in each PCR run. Sections from spleens of 9 mice (3 from each of the acutely infected, chronically infected, and control groups) were collected and processed for routine histopathological examination. Briefly, tissues were fixed in 10% neutral formaldehyde solution for 1 week, dehydrated in a graded series of ethanol, embedded in paraffin wax, cut into 5 μm-thick serial sections on a microtome, stained with hematoxylin-eosin (H&E), and finally examined under an optical microscope (Olympus, Tokyo, Japan).

Metabolite extraction

A total of 30 spleen samples were collected from two different infection groups (acutely infected, n = 10; chronically infected, n = 10) plus a control group (n = 10). Samples were gradually transferred from -80 °C to -20 °C and then to 4 °C. The organic protein precipitation method was used to extract metabolites. Briefly, 25 mg splenic tissues that were collected from a homogenous mixture of the whole spleen were ground in a mortar in liquid nitrogen. Then, 800 μl methanol/water (1:1) solution and 3 mm (mean diameter) steel beads were added to each sample. Using a TissueLyser bead-mill homogenizer (Qiagen, Hilden, Germany), samples were homogenized via vibrating at 60 Hz for 5 min. Subsequently, samples were centrifuged at 25,000× g for 10 min at 4 °C. The supernatant of each sample was separated and freeze-dried. Also, 200 μl supernatant of each sample were pooled and used as quality control (QC) samples. Finally, freeze-dried samples were reconstituted, and subjected to mass spectrometry analysis.

LC-MS/MS analysis

Unbiased metabolomics analysis was performed using an ultra-performance liquid chromatography (UPLC) system (Waters, Milford, USA). The chromatographic separation was carried out using an ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm, Waters) with a column temperature of 50 °C and a flow rate of 0.4 ml/min, where the mobile phase contained solvent A (water +0.1% formic acid) and solvent B (acetonitrile +0.1% formic acid). Metabolites were eluted using the following gradient elution conditions: 100% phase A for 0–2 min; 0–100% phase B for ~11 min; 100% phase B for 11–13 min; 100% Phase A for 13–15 min. The loading volume of each sample was 10 μl. The metabolites eluted from the column were detected by a high-resolution tandem mass spectrometer SYNAPT G2 XS QTOF (Waters) in positive and negative ion modes. For positive ion mode, the capillary voltage and the cone voltage were set at 2 kV and 40 V, respectively. For negative ion mode, they were 1 kV and 40 V, respectively. Centroid MSE mode was used to collect the mass spectrometry data. The primary scan ranged from 50 to 1200 Da and the scanning time was 0.2 s. All the parent ions were fragmented using 20–40 eV. The information of all fragments were collected and the time was 0.2 s. In the data acquisition process, the LE signal was gained every 3 s for real-time quality correction. Furthermore, quality control samples (10 samples) were collected to evaluate the stability of the instrument during measurements.

Multivariate statistical analysis

The raw mass spectrometry data were processed, extracted and the peaks were identified. This procedure involved chromatogram alignment, peak picking, peak area extraction and normalization by commercial software progenesis QI (version 2.2) implementation. Multivariate statistical analyses (principal components analysis, PCA; partial least squares-discriminant analysis, PLS-DA) were performed to discriminate infected mice from control mice. PLS-DA has been widely used in high-dimensional data analysis, especially in the field of metabolomics to maximize group separation [21, 22]. Differentially expressed metabolites were identified on the basis of variable importance in the projection (VIP) threshold ≥ 1 from the PLS-DA model and P-values obtained from a two-tailed, Student’s t-test on the normalized peak areas < 0.05. The values of R 2 and Q 2 parameters were used to verify the fitness and predictive ability of the model. Fold change (FC) was set to be ≥ 1.2 or ≤ 0.8333. Log2 FC based on metabolite abundance was used to assess the levels of variation of the differential metabolites between various mouse groups. Data converted to log2 format were used in cluster analysis and generation of heat-maps to show the distinction in the metabolic state between infected mice and controls, and between infected mice at different stages of infection.

Metabolite identification and pathway analysis

We used the online HMDB (http://www.hmdb.ca/) and KEGG (www.genome.jp/kegg/) databases to identify the metabolites by matching the exact molecular mass data (m/z) of samples with those from the database. If a mass difference between the observed value and the database value was less than 10 ppm, the metabolite would be identified and the molecular formula of the metabolites would further be validated by the isotopic distribution measurement. Reference standards were used to validate and confirm those significantly changed metabolites by comparing their MS/MS spectra and retention times. Metabolic enrichment analysis was performed to identify and visualize the affected pathway in T. gondii-infected mice using the MetPA web tool (http://www.metaboanalyst.ca/) [23].

Results

Toxoplasma gondii infection in mice

Infected mice exhibited mild clinical signs, such as loss of appetite and ruffled hair coat at 7 dpi. These signs progressed and became more evident at 11 dpi, correlating with the acute stage of infection. However, mice began to recover after ~14 dpi and by 30 dpi all mice had developed chronic infection. Therefore, 11 dpi and 30 dpi were selected to represent the acute and chronic phases of infection, respectively. Infection was confirmed in all infected mice by positive PCR results. By contrast, mice in the control group appeared normal and yielded negative PCR results. Histopathology showed splenomegaly in the acutely infected mice (Fig. 1a), but slightly less enlargement in the spleen of chronically infected mice (Fig. 1b). A reduction in the white pulp, but an expansion of the red pulp was observed in the spleen of acutely infected mice (Fig. 1c). By contrast, white pulp hyperplasia with nonreactive red pulp was less prominent in the spleen during chronic infection (Fig. 1d). Spleens of control, uninfected, mice did not show any gross anatomical or histopathological abnormalities (Fig. 1a, b, e).
Fig. 1

Gross and histopathological characteristics of spleen of mice infected with Toxoplasma gondii. a The spleen of mice during acute infection (AI) was enlarged compared to normal spleen size of mice in the control group (Con). b Mouse spleen during chronic infection (CI) showing slight splenomegaly compared to control (Con) mice. c Histopathology of spleen from acutely infected mouse showing a reduction in the white pulp with an expansion of the red pulp compartment. d Spleen of a chronically infected mouse showing regression of white pulp and red pulp. e Spleen of a healthy mouse showing no histopathological abnormalities. Scale-bars: c-e, 12.5 μm

Metabolic profiles of mouse groups

Mass spectrometry data were analyzed by multivariate statistics to discriminate infected mice from controls. There were 5308 and 6641 molecular features; relative standard deviation (RSD) ≤ 30% ion number of 3702 and 4408; and ratio of 78.30 and 75.08% detected in the positive electrospray ionization (ESI+) mode and negative (ESI-) mode, respectively. Next, we analyzed RSD ≤ 30% ion chromatograms. The total ion chromatograms (TIC) overlap and the PCA scores plot representation of QC samples were performed and confirmed the repeatability and stability of the mass spectrometry measurement, as shown in Fig. 2 (ESI+) and Additional file 1: Figure S1 (ESI-). However, the PCA scores plot did not show any clear separation between the infected and control mice. To better elucidate the metabolic differences, PLS-DA analysis was performed and the score plots are displayed in Fig. 3a, b (ESI+) and Additional file 2: Figure S2 a, b (ESI-). The PLS-DA model of acutely infected vs control (R 2 = 0.913, Q 2 = 0.5136, ESI+; R 2 = 0.9237, Q 2 = 0.4026, ESI-) and chronically infected vs control (R 2 = 0.867, Q 2 = 0.5184, ESI+; R 2 = 0.8848, Q 2 = 0.3388, ESI-) showed a high degree of segregation between the mouse groups. The parameters R 2 and Q 2 confirmed the validity of the model. Also, the score plots showed clear discrimination between different infected mouse groups and the control group in both the positive and negative electrospray ionization modes.
Fig. 2

a The total ion current (TIC) chromatograms of spleen samples in the positive ion mode (ESI+). b PCA scores plot of mice spleens, including acutely infected (AI), chronically infected (CI) and uninfected control (Con) compared to quality control (QC) samples in the positive ion mode (ESI+). Clear separation was detected among the different mice groups and in relation to QC samples

Fig. 3

a, b Two dimensional PLS-DA score plots of the a acutely infected mice and b chronically infected mice vs control mice in the positive ion mode (ESI+). Each dot represents one spleen sample, projected onto first (horizontal axis) and second (vertical axis) PLS-DA variables. Mice groups are shown in different colors. The ellipse determines the 95% confidence interval. c, d Heatmaps of the differential metabolites of acutely infected mice c and chronically infected mice d vs control mice in the positive ion mode (ESI+). Red and green indicate values above and below the mean, respectively; black indicates values close to the mean

Differential abundance of metabolites by infection phases

The differential metabolites between different mouse groups were categorized according to the stage of infection. The results (Additional file 3: Table S1) show the upregulated and downregulated metabolites between different mouse groups. These differential metabolites between different mouse groups were used for clustering analysis and heatmaps, as shown in Fig. 3c, d (ESI+) and Additional file 2: Figure S2c, d (ESI-). The heatmaps showed a clear difference between acutely infected mice and control mice. Although there was an outlier data point in acutely infected mice in the negative ion mode (Additional file 2: Figure S2a), the same data point clustered with the other points in the same mouse group in the positive ion mode (Fig. 3a). By contrast, chronically infected group was not clearly separated from the control group. In the positive and negative modes, two individuals in the chronically infected group clustered with the control group. Finally, 132 significant metabolites were identified, 23 from acutely infected group vs control and 109 from chronically infected vs control, as shown in Additional file 4: Table S2 and Additional file 5: Table S3, respectively. These metabolites included lipids, hormones, lactones, acids, peptides, antibiotics, alkaloids and natural toxins. There were 32 metabolites involved in wide range metabolic pathways (Table 1). Venn diagram was developed to correlate metabolites to the infection phase (Fig. 4). The acutely infected group vs control and chronically infected vs control shared 12 differential metabolites. Also, 4,4-Dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol was significantly upregulated and Ubiquinone-8 was significantly downregulated. However, levels of arachidonic acid (AA) were different between acute and chronic infection phases (Table 2).
Table 1

List of identified differential metabolites involved in the perturbed metabolic pathways during acute and chronic phases of Toxoplasma gondii infection

Mice group

Ionization method

m/z - RT

Metabolites

VIP

FC

q-value

Metabolic pathways

AI vs Con

ESI (+)

369.205–5.980

Corticosterone

2.843

3.049

0.017

Steroid hormone biosynthesis; Regulation of lipolysis in adipocytes; Aldosterone synthesis and secretion

433.342–7.128

4,4-Dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol

5.216

9.497

0.040

Steroid biosynthesis

299.197–7.263

Stearidonic acid

1.819

0.732

0.025

alpha-Linolenic acid metabolism

453.293–7.612

7alpha-Hydroxy-3-oxo-4-cholestenoate

1.462

0.704

0.026

Primary bile acid biosynthesis

454.390–7.684

3alpha,7alpha,12alpha,26-Tetrahydroxy-5beta-cholestane

1.369

0.331

0.011

Primary bile acid biosynthesis

331.224–7.727

17alpha,21-Dihydroxypregnenolone

1.907

0.550

0.035

Steroid hormone biosynthesis

709.559–8.548

Ubiquinone-8

4.574

0.0565

0.040

Ubiquinone and other terpenoid-quinone biosynthesis

ESI (−)

303.232–7.199

Arachidonic acid

1.271

0.652

0.045

Arachidonic acid metabolism; Linoleic acid metabolism; Biosynthesis of unsaturated fatty acids; Vascular smooth muscle contraction; Platelet activation; Fc epsilon RI signaling pathway; Fc gamma R-mediated phagocytosis; Retrograde endocannabinoid signaling; Serotonergic synapse; Long-term depression; Inflammatory mediator regulation of TRP channels; GnRH signaling pathway; Ovarian steroidogenesis; Oxytocin signaling pathway; Regulation of lipolysis in adipocytes; Aldosterone synthesis and secretion

453.161–8.588

Methotrexate

1.537

0.731

0.047

Bile secretion

CI vs Con

ESI (+)

433.342–7.128

4,4-Dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol;

4.660

6.459

0.046

Steroid biosynthesis

454.390–7.684

3alpha,7alpha,12alpha,26-Tetrahydroxy-5beta-cholestane

1.185

0.385

0.014

Primary bile acid biosynthesis

385.344–7.886

Cerebrosterol

2.976

8.236

0.046

Primary bile acid biosynthesis

361.150–8.322

Neamine

3.163

4.633

0.023

Butirosin and neomycin biosynthesis; Biosynthesis of antibiotics

305.214–8.519

19-Hydroxytestosterone

1.896

1.669

0.049

Steroid hormone biosynthesis

351.229–8.533

Docosahexaenoic acid(DHA)

1.113

1.331

0.033

Biosynthesis of unsaturated fatty acids

709.559–8.548

Ubiquinone-8

7.038

0.019

0.002

Ubiquinone and other terpenoid-quinone biosynthesis

391.284–8.943

Bile acid

1.342

1.470

0.037

Fat digestion and absorption; Vitamin digestion and absorption

365.194–8.994

Phorbol

1.464

1.483

0.029

Inflammatory mediator regulation of TRP channels

419.350–9.386

7alpha,27-Dihydroxycholesterol

1.509

2.112

0.032

Primary bile acid biosynthesis

425.339–9.728

7alpha-Hydroxycholesterol

2.029

2.228

0.006

Primary bile acid biosynthesis

343.195–8.563

Arachidonic acid

2.132

1.757

0.015

Arachidonic acid metabolism; Linoleic acid metabolism; Biosynthesis of unsaturated fatty acids; Vascular smooth muscle contraction; Platelet activation; Fc epsilon RI signaling pathway; Fc gamma R-mediated phagocytosis; Retrograde endocannabinoid signaling; Serotonergic synapse; Long-term depression; Inflammatory mediator regulation of TRP channels; GnRH signaling pathway; Ovarian steroidogenesis; Oxytocin signaling pathway; Regulation of lipolysis in adipocytes; Aldosterone synthesis and secretion;

ESI (−)

295.227–10.292

(9S)-Hydroxyoctadecadienoic acid

1.707

0.702

0.020

Linoleic acid metabolism; PPAR signaling pathway

317.210–7.655

Leukotriene A4

1.364

1.623

0.020

Arachidonic acid metabolism; Serotonergic synapse

315.195–8.218

15-Deoxy-delta-12,14-PGJ2

1.834

1.942

0.005

Arachidonic acid metabolism

319.189–8.325

Ubiquinol

2.203

2.424

0.038

Oxidative phosphorylation

301.215–8.353

(5Z,7E,9E,14Z,17Z)-Eicosapentaenoate

3.001

3.042

0.017

Inflammatory mediator regulation of TRP channels

289.216–8.328

Androstenediol

2.718

3.058

0.048

Steroid hormone biosynthesis; Ovarian steroidogenesis

550.264–8.439

Taurocholate

1.654

1.936

0.023

Primary bile acid biosynthesis; Taurine and hypotaurine metabolism; Bile secretion

371.179–8.511

Biocytin

1.024

0.806

0.030

Biotin metabolism; Vitamin digestion and absorption

543.151–8.525

Premithramycin A1

2.026

0.598

0.030

Biosynthesis of antibiotics

416.316–8.571

N-Oleoyl dopamine

2.167

3.359

0.024

Neuroactive ligand-receptor interaction

453.161–8.588

Methotrexate

1.686

0.701

0.008

Bile secretion

569.166–8.588

5″-Phosphoribostamycin

1.823

0.538

0.045

Butirosin and neomycin biosynthesis

305.247–8.774

(8Z,11Z,14Z)-Icosatrienoic acid

1.630

1.519

0.031

Linoleic acid metabolism; Biosynthesis of unsaturated fatty acids

307.262–9.009

Icosadienoic acid

1.767

1.819

0.006

Biosynthesis of unsaturated fatty acids

337.326–9.024

14,15-DHET

1.702

1.557

0.029

Arachidonic acid metabolism; Serotonergic synapse

283.262–9.238

Octadecanoic acid

1.134

1.207

0.007

Fatty acid biosynthesis; Biosynthesis of unsaturated fatty acids

Abbreviations: m/z - RT, MS and retention time; VIP, variable importance for projection; FC, fold change; q-value, adjusted P-value calculated by two-tailed Wilcoxon rank-sum tests after false discovery rate correction

Fig. 4

A two-way Venn diagram showing the common and unique metabolites between acutely and chronically infected mice groups vs control mice. In total, we found 23 metabolites in acute infection vs control (blue), of which 12 metabolites could also be identified in chronically infected mice. Also, we detected 109 metabolites in the chronically infected mice vs control (yellow), 12 of which were shared between the groups

Table 2

List of common metabolites in acute and chronic phases of Toxoplasma gondii infection

KEGG.ID

Metabolite

Differentially expressed metabolitea

  

Acutely infected

Chronically infected

C11455

4,4-Dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol

C05446

3alpha,7alpha,12alpha,26-Tetrahydroxy-5beta-cholestane

C13804

ORG 20599

C17569

Ubiquinone-8

C11606

NAc-FnorLRF-amide

C00219

Arachidonic acid

C16147

Glycosyl-4,4′-diaponeurosporenoate

C16885

Gambieric acid A

C09261

Disenecionyl cis-khellactone

C10458

Furcatin

C01937

Methotrexate

C14668

Cortancyl

a↑, upregulated; ↓, downregulated

Metabolic pathways affected by infection phases

Metabolite enrichment analysis was performed and several metabolic pathways were found to be influenced by infection. As shown in Fig. 5a and Table 3, the metabolic pathways identified during acute infection involved primary bile acid biosynthesis, steroid hormone biosynthesis, arachidonic acid metabolism and steroid biosynthesis, among others. Some of the impacted pathways during chronic infection involved primary bile acid biosynthesis, steroid hormone biosynthesis, biotin metabolism, arachidonic acid metabolism and steroid biosynthesis (Fig. 5b, Table 4). The most deeply impacted pathway during both acute and chronic infection was the arachidonic acid metabolism. An illustration of AA metabolism pathway is provided to show specific metabolites dysregulated during chronic infection (Fig. 5c).
Fig. 5

Pathway analysis of the differential metabolites during acute and chronic infection. Metabolite features with putative identification were analyzed using MetaboAnalyst for potential impact on metabolic pathways in the acute phase a and chronic phase b. Small P-value and large pathway impact factor indicate that the pathway is greatly influenced, such as arachidonic acid metabolism pathway, which was highly impacted during acute and chronic infection. c A schematic illustration of the arachidonic acid metabolism pathway during chronic infection. Red and black circles represent upregulated and unaltered metabolites, respectively. As shown, arachidonic acid (AA), leukotriene A4 (LTA4), 14,15-HETE, and 15-deoxy-Δ12,14-PGJ2 were upregulated

Table 3

Summary of the pathway analysis using MetaboAnalyst during acute Toxoplasma gondii infection

Metabolic pathway

Raw P-valuea

-log(p)

Impactb

Arachidonic acid metabolism

0.2473

1.3971

0.3260

Steroid biosynthesis

0.2413

1.4219

0.1245

Steroid hormone biosynthesis

0.1041

2.2623

0.0578

Primary bile acid biosynthesis

0.0471

3.0561

0.0102

aRaw P-value is the original P-value calculated from the enrichment analysis

bImpact is the pathway impact value calculated from pathway topology analysis

Table 4

Summary of the pathway analysis using MetaboAnalyst during chronic Toxoplasma gondii infection

Metabolic pathway

Raw P-valuea

-log(p)

Impactb

Arachidonic acid metabolism

0.1664

1.7935

0.4042

Biotin metabolism

0.0984

2.3191

0.3000

Steroid biosynthesis

0.5194

0.6551

0.1245

Primary bile acid biosynthesis

0.0019

6.2581

0.0724

aRaw P-value is the original P value calculated from the enrichment analysis

bImpact is the pathway impact value calculated from pathway topology analysis

Discussion

The aim of this work was to elucidate the effect of T. gondii infection on the metabolism of mouse spleen, a key organ in regulating immune response against T. gondii infection. LC-MS/MS-based metabolomics and multivariate statistical analyses revealed new metabolic changes in the spleen of T. gondii-infected mice compared with uninfected mice and identified metabolic signatures that differentiated between the acute infection and chronic infection.

Stage-specific metabolic signatures

A total of 389 differential ions were screened based on using VIP scores (VIP > 1) of individual metabolites obtained from the PLS-DA model. We succeeded to identify 259 of the 389 differential ions, which highlights the challenges associated with the identification of metabolites. We used heatmaps to present the results of these differential ions between different mouse groups. The heatmaps showed a clear difference between acutely infected group and the control group (Fig. 3c, Additional file 2: Figure S2c), but chronically infected group was not fully distinct from the control group (Fig. 3d, Additional file 2: Figure S2d). In the positive and negative modes, two mice in the chronically infected group were clustered with mice in the control group, which could be attributed to inter-individual variations among chronically infected mouse group. Also, converging metabolic responses between these two chronically infected and control mice is probably due to homeostatic recovery that might have occurred as infection progressed to the chronic phase. Interestingly, we identified 132 significantly altered metabolites, 23 from acutely infected vs control and 109 from chronically infected vs control mice (Additional file 4: Table S2, Additional file 5: Table S3), suggesting that as infection progressed the number of differential metabolites increased. This result disagrees with previous metabolomic profiling of serum [12] and brain [13] of T. gondii-infected mice where the most predominant metabolic changes, compared with control mice, happened at an early stage of infection. These distinct temporal metabolic patterns between metabolomics studies can be attributed to organ-specific metabolomics organization (i.e. different repertoire of small molecules present in different organs). Also, the metabolomic response to infection of a major peripheral immune organ such as spleen, is expected to be different from that of the serum [12] or brain [13].

There were 12 shared differential metabolites between the acute and chronic infection phases (Table 2, Fig. 4). 4,4-Dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol was significantly upregulated and ubiquinone-8 was significantly downregulated, suggesting that these two metabolites might play important roles during T. gondii infection. The upregulation of 4,4-Dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol during both acute and chronic phases might be related to the regulatory effect of this molecule on host cell meiosis [24]. Expression patterns of AA were distinct between the acute and chronic infection phases (i.e. infection stage-specific). As shown in Additional file 4: Table S2 and Additional file 5: Table S3, in the two infection phases, most of the identified differential metabolites were lipids, which are essential for the biogenesis of cell and parasite membranes in order to ensure parasite’s survival and replication within host cells [25].

We chose spleen in this study because of its importance in immune surveillance during infection. Spleen comprises two morphologically and functionally distinct regions (red pulp and white pulp) and contains multiple subsets of specialized myeloid and dendritic cells. However, a major drawback of splenic tissue is its complex and dynamic cellular heterogeneity especially in response to infection. In the present study, T. gondii infection induced spatial alterations in the composition of splenic cellular populations and splenomegaly was a relatively sub-fatal complication of infection. These changes could have a profound effect on the metabolome of this tissue and consequently make it hard to dissociate the direct effect of infection on metabolite expression patterns from the contribution of the anatomical abnormalities associated with infection. Therefore, it is possible that changes we observed in the levels of metabolites is a consequence of the differential contributions of cellular populations of spleen from acute, chronic and control mice rather than the result of actual changes in the metabolic activity in spleen cells triggered by T. gondii infection per se. Precise mechanisms, however, remain unclear and the specific contributions of the metabolites of the red and white pulps to the alterations in the levels of metabolites observed during T. gondii infection remains to be clarified.

The impact on host defense mechanisms

In the acute phase, the level of corticosterone was markedly increased with log2 fold change of 3.049. Hormones are very important signaling molecules in mammals and are fundamental for their metabolic and immune homeostasis [26]. Corticosterone is vital in the metabolism of carbohydrates, fatty acids and amino acids. The markedly altered corticosterone might reflect variations in the energy metabolism in the spleen of infected mice, which might be triggered by illness-related anorexia. Ubiquinol of the oxidative phosphorylation pathway was probably upregulated to supply energy needed by the body to balance its metabolic status during the latent phase of infection. The anti-fungal molecule gambieric acids A [27] and the antibiotic molecules, neamine and difloxacin (INN), were also significantly upregulated. Additionally, AA, Phorbol and (5Z,7E,9E,14Z,17Z)-Eicosapentaenoate, which act as inflammatory mediators, were upregulated. It is likely that spleen defends against T. gondii infection not only by specific immune processes, but also by eliciting different metabolic reactions as part of the innate immunity to limit the infection.

Toxoplasma gondii infection disturbs eicosanoid metabolism

The altered metabolic pathways identified involved primary bile acid biosynthesis, steroid biosynthesis and arachidonic acid metabolism. Steroid hormones are involved in a variety of physiological processes; relevant to T. gondii pathogenesis are the immunoregulatory and anti-inflammatory effects of steroids, which can influence the host immune responses to infection [28]. Our results also revealed AA metabolism, the main precursor of eicosanoid hormones, as the most significantly affected metabolic pathway by T. gondii during acute and chronic infection. At 11 dpi, the level of AA decreased, indicating down-regulation of AA metabolism during acute infection. By contrast, at 30 dpi the level of AA was significantly upregulated in the chronic phase (Fig. 5c). The major inflammatory mediators, LTA4, 14,15-HETE, and 15-deoxy-Δ12,14-PGJ2 [2931], were also up-regulated. In response to an inflammatory stimulus, AA, the main polyunsaturated fatty acid present in the phospholipid of cell membranes, is released and metabolized to a series of eicosanoids, including the inflammatory leukotrienes and prostanoids (e.g. prostaglandins, prostacyclins and thromboxanes) [32]. AA and its eicosanoid metabolites play an important role in the regulation of many cellular processes, such as cell survival, angiogenesis, chemotaxis, mitogenesis, apoptosis and migration [33, 34]. Elevated level of AA in the supernatant of T. gondii-infected cultured J774A.1 cells was assumed to be triggered by increased Phospholipase A production in order to release AA via decomposing the host cell membrane phospholipids, thus promoting the parasites invasion by increasing the host cell membrane permeability and fluidity [35]. Likewise, T. gondii was shown to increase AA concentration and agglutination of microfilaments in phagocytic host cells to accelerate the parasite’s invasion [35].

Conclusions

We employed global LC-MS/MS-based metabolomics to detect differential metabolites in the spleen of mice infected with T. gondii and to identify changes in metabolic pathways with direct relevance to the parasite pathogenesis. Our research demonstrated that significant metabolomic impairments occur in the spleen of mice infected with T. gondii. These included hormones, lactones, acids, peptides, antibiotics, alkaloids, natural toxins and others. Abnormal metabolism of these metabolites could play various roles in immune response and inflammatory reaction during T. gondii infection. Our study also revealed infection stage-specific metabolites, such as arachidonic acid. More differentially expressed metabolites were detected in the chronic phase compared with the acute phase. Further, we detected perturbations in biochemical pathways, including primary bile acid biosynthesis, steroid hormone biosynthesis, biotin metabolism, arachidonic acid metabolism and steroid biosynthesis, involved in the proper functioning of the spleen, which might underpin the dysregulation in systemic immunity in toxoplasmosis. The knowledge of spleen metabolomic differences by disease severity (acute vs chronic stage of T. gondii infection) has potential clinical implications in the development of optimal therapies.

Abbreviations

AA: 

Arachidonic acid

AI: 

Acutely infected

CI: 

Chronically infected

Con: 

Uninfected control

dpi: 

Days post-infection

ESI-: 

Negative electrospray ionization

ESI+: 

Positive electrospray ionization

FC: 

Fold change

LTA4: 

Leukotriene A4

PCA: 

Principal components analysis

PLS-DA: 

Partial least squares discriminant analysis

QC: 

Quality control

TIC: 

Total ion chromatograms

VIP: 

Variable importance in the projection

Declarations

Acknowledgements

The authors would like to thank BGI Bioinformatics Technology Co., Ltd. (Shenzhen, China) for performing the preliminary data analysis.

Funding

Project support was provided by the National Natural Science Foundation of China (Grant No. 31230073) and by the Fundamental Research Funds of Chinese Academy of Agricultural Sciences (Grant No. Y2016JC05).

Availability of data and materials

The datasets supporting the findings of this article are included within the article. The metabolomics data are available in the MetaboLights database (MTBLS438) (http://www.ebi.ac.uk/metabolights).

Authors’ contributions

XQZ, HME and GXH conceived and designed the study and critically revised the manuscript. XQC and CXZ performed the experiments. XQC analyzed the data and drafted the manuscript. SH helped in the implementation of the study. All authors read and approved the final manuscript.

Ethics approval

All experiments were conducted with the approval of the Animal Administration and Ethics Committee of Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences (Permit No. LVRIAEC2016–007). All animals were handled in strict accordance with good laboratory animal practice according to the Animal Ethics Procedures and Guidelines of the People’s Republic of China. All efforts were made to minimize animal suffering.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Veterinary Medicine, College of Animal Science and Technology, Jilin Agricultural University
(2)
State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences
(3)
Department of Parasitology, Shandong University School of Basic Medicine
(4)
Faculty of Medicine and Health Sciences, School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus
(5)
College of Animal Science and Technology, Anhui Agricultural University

References

  1. Dubey JP. The history of Toxoplasma gondii - the first 100 years. J Eukaryot Microbiol. 2008;55:467–75.View ArticlePubMedGoogle Scholar
  2. Weiss LM, Dubey JP. Toxoplasmosis: a history of clinical observations. Int J Parasitol. 2009;39:895–901.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Elsheikha HM. Congenital toxoplasmosis: priorities for further health promotion action. Public Health. 2008;122:335–53.Google Scholar
  4. Dupont CD, Christian DA, Hunter CA. Immune response and immunopathology during toxoplasmosis. Semin Immunopathol. 2012;34:793–813.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Munoz M, Liesenfeld O, Heimesaat MM. Immunology of Toxoplasma gondii. Immunol Rev. 2011;240:269–85.View ArticlePubMedGoogle Scholar
  6. Johnson LL. SCID mouse models of acute and relapsing chronic Toxoplasma gondii infections. Infect Immun. 1992;60:3719–24.PubMedPubMed CentralGoogle Scholar
  7. Yarovinsky F. Innate immunity to Toxoplasma gondii infection. Nat Rev Immunol. 2014;14:109–21.View ArticlePubMedGoogle Scholar
  8. Kang H, Remington JS, Suzuki Y. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. J Immunol. 2000;164:2629–34.Google Scholar
  9. Peter CS, George WG, Lawrence LJ. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect Immun. 2000;68:1026–33.View ArticleGoogle Scholar
  10. Li P, Yin YL, Li D, Kim SW, Wu G. Amino acids and immune function. Br J Nutr. 2007;98:237–52.View ArticlePubMedGoogle Scholar
  11. Gonzálezdomínguez R, Garcíabarrera T, Vitorica J, Gómezariza JL. Metabolomics reveals significant impairments in the immune system of the APP/PS1 transgenic mice of Alzheimer's disease. Electrophoresis. 2015;36:577–87.View ArticleGoogle Scholar
  12. Zhou CX, Zhou DH, Elsheikha HM, Zhao Y, Suo X, Zhu XQ. Metabolomic profiling of mice serum during toxoplasmosis progression using liquid chromatography-mass spectrometry. Sci Rep. 2016;6:19557.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Zhou CX, Zhou DH, Elsheikha HM, Liu GX, Suo X, Zhu XQ. Global metabolomic profiling of mice brains following experimental infection with the cyst-forming Toxoplasma gondii. PLoS One. 2015;10:e0139635.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Elsheikha HM, Zhu XQ. Toxoplasma gondii infection and schizophrenia: an inter-kingdom communication perspective. Curr Opin Infect Dis. 2016;29:311.View ArticlePubMedGoogle Scholar
  15. Aliberti J. Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii. Nat Rev Immunol. 2005;5:162–70.View ArticlePubMedGoogle Scholar
  16. Zaretsky AG, Silver JS, Siwicki M, Durham A, Ware CF, Hunter CA. Infection with Toxoplasma gondii alters lymphotoxin expression associated with changes in splenic architecture. Infect Immun. 2012;80:3602–10.View ArticleGoogle Scholar
  17. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008;134:714–7.View ArticlePubMedGoogle Scholar
  18. Olszewski KL, Morrisey JM, Wilinski D, Burns JM, Vaidya AB, Rabinowitz JD, et al. Host-parasite interactions revealed by Plasmodium falciparum metabolomics. Cell Host Microbe. 2011;5:191–9.View ArticleGoogle Scholar
  19. Pittman KJ, Aliota MT, Knoll LJ. Dual transcriptional profiling of mice and Toxoplasma gondii during acute and chronic infection. BMC Genomics. 2014;15:806.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Hill DE, Chirukandoth S, Dubey JP, Lunney JK, Gamble HR. Comparison of detection methods for Toxoplasma gondii in naturally and experimentally infected swine. Vet Parasitol. 2006;141:9–17.View ArticlePubMedGoogle Scholar
  21. Bryan K, Brennan L, Cunningham P. Metafind: a feature analysis tool for metabolomics data. BMC Bioinformatics. 2008;9:470.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Zhang T, Wu X, Ke C, Yin M, Li Z, Fan L, et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res. 2013;12:505–12.View ArticlePubMedGoogle Scholar
  23. Xia J, Wishart DS. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc. 2011;6:743–60.View ArticlePubMedGoogle Scholar
  24. Thorsten B, Peter E, Joachim K. Preparation of 4,4-dimethyl-5-alpha-cholesta-8,14,24-trien-3-beta-ol useful as meiosis regulator for the promotion of fertility. 1999;German Patent DE19817520.Google Scholar
  25. Gupta N, Zahn MM, Coppens I, Joiner KA, Voelker DR. Selective disruption of phosphatidylcholine metabolism of the intracellular parasite Toxoplasma gondii arrests its growth. J Biol Chem. 2005;280:16345–53.View ArticlePubMedGoogle Scholar
  26. Daynes RA, Araneo BA, Hennebold J, Enioutina E, Mu HH. Steroids as regulators of the mammalian immune response. J Invest Dermatol. 1995;105(Suppl. 1):14S–9S.View ArticlePubMedGoogle Scholar
  27. Nagai H, Torigoe K, Satake M, Murata M, Yasumoto T, Hirota H. Gambieric acids: unprecedented potent antifungal substances isolated from cultures of a marine dinoflagellate Gambierdiscus toxicus. J Am Chem. 1992;23:1102–3.View ArticleGoogle Scholar
  28. Tait AS, Butts CL, Sternberg EM. The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease. J Leukoc Biol. 2008;84:924–31.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Negishi M, Koizumi T, Ichikawa A. Biological actions of delta 12-prostaglandin J2. J Lipid Mediat Cell Signal. 1995;12:443–8.View ArticlePubMedGoogle Scholar
  30. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–6.View ArticlePubMedGoogle Scholar
  31. Khanapure SP, Garvey DS, Janero DR, Letts LG. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem. 2007;7:311–40.View ArticlePubMedGoogle Scholar
  32. Greene ER, Huang S, Serhan CN, Panigrahy D. Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat. 2011;96:27–36.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Rizzo MT, Regazzi E, Garau D, Akard L, Dugan M, Boswell HS, et al. Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells. Cancer Res. 1999;59:5047–53.PubMedGoogle Scholar
  34. Levick SP, Loch DC, Taylor SM, Janicki JS. Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol. 2007;178:641–6.View ArticlePubMedGoogle Scholar
  35. Li L, Li X, Yan J. Alterations of concentrations of calcium and arachidonic acid and agglutinations of microfilaments in host cells during Toxoplasma gondii invasion. Vet Parasitol. 2008;157:21–3.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Advertisement